In a Healio video exclusive, Dr. Michael V. Chiorean discusses how physicians can safely switch patients with inflammatory bowel disease from originator biologics to biosimilars at any point during treatment. Research shows that switching to biosimilars is safe, with no differences in drug pharmacokinetics or clinical activities before and after the switch. Chiorean emphasizes that patients are receiving the same drug under a different brand name when switching to a biosimilar. The use of biosimilars is expected to reduce costs of care, increase access to effective therapies, and improve outcomes for patients with severe and debilitating diseases like IBD.
Source link
OK to switch patients with IBD from biologic to biosimilar âat any given timeâ
